氯虫腈中毒:系统综述
本文系统检索PubMed、Web of Science、Google Scholar和EMBASE(截至2024年4月),纳入48篇文献共75例经摄入、吸入、皮肤接触及腹腔内注射氯虫腈中毒病例。暴露至症状出现中位时间6小时(四分位距1-48小时),61%患者出现高热且与病情恶化和死亡时间相关,中枢神经系统影像常见对称性白质异常伴肿胀,病死率76%,存活者常遗留持续性神经后遗症。管理策略差异很大,特定医疗干预有效性不明确。作者认为采取密切临床监测和支持治疗的保守策略是审慎的。
要点
- 暴露至症状出现中位时间6小时(四分位距1-48小时),潜伏期可长达14天,需警惕延迟恶化。
- 61%患者出现高热(≥38℃),与临床恶化和死亡时间相关,为不祥临床征象。
- 常见实验室异常为血肌酸激酶活性、肝转氨酶活性和乳酸浓度升高,仅肌酸激酶活性在存活者与死亡者间存在差异。
- 中枢神经系统影像常显示广泛对称性白质异常伴肿胀。
- 病死率76%,存活者常遗留持续性神经后遗症;管理策略差异大,特定干预有效性不明确。
适用人群与场景
- 纳入:经摄入、吸入、皮肤接触或腹腔内注射氯虫腈后急性暴露的人类病例,须有暴露、临床表现和临床病程描述。
- 排除:体外研究、动物研究、农业研究、环境影响研究和非临床人体研究。
- 场景:急诊或重症监护中急性人类氯虫腈暴露患者。
诊断标准与关键阈值
- 高热定义为体温≥38℃。
处置流程与药物剂量
- 作者认为采取保守策略、密切临床监测和支持治疗是审慎的。
- 管理策略高度多样,特定医疗干预的有效性不明确。
红旗征与不能漏的情况
- 高热(≥38℃)为不祥临床征象,与临床失代偿和死亡时间相关。
- 潜伏期可长达14天,之后数小时至数天内恶化,可导致危重病情。
- 肌酸激酶活性在存活者与死亡者间存在差异。
研究设计与关键结果
- 系统综述纳入48篇文献,描述75例经摄入、吸入、皮肤接触和腹腔内注射氯虫腈的中毒病例,未发现三氟吡啶暴露病例。
- 暴露至症状出现中位时间6小时(四分位距1-48小时);最常见初始或就诊症状/体征包括出汗、恶心和/或呕吐、精神状态改变。
- 就诊时高热(≥38℃)较少见,但61%患者出现高热,且与临床恶化和死亡时间相关。
- 最常见实验室异常包括血肌酸激酶活性、肝转氨酶活性和乳酸浓度升高;仅肌酸激酶活性在存活者与死亡者间存在差异。
- 中枢神经系统影像常显示广泛对称性白质异常伴肿胀。
- 病死率76%,存活者常遗留持续性神经后遗症;管理策略高度多样,特定医疗干预有效性不明确。
证据类型、等级与局限
- 证据类型:系统综述(PRISMA指南),检索PubMed、Web of Science、Google Scholar和EMBASE至2024年4月,所有语言。
- 局限:所有综述固有的回顾性和观察性性质,以及发表偏倚强调严重结局,影响疾病谱并使死亡率百分比偏倚。
- 局限:仅检索有限数量数据库,且实验室检测确认氯虫腈中毒的病例有限。
- 局限:分析未把握检测组间差异,未进行比较统计,未报告显著性。
对床旁实践的改变
- 作者认为对急性氯虫腈暴露患者采取保守策略、密切临床监测和支持治疗是审慎的。
- 管理策略高度多样且特定医疗干预有效性不明确,临床决策需个体化。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: Chlorfenapyr, a N-substituted halogenated pyrrole, is a broad-spectrum insecticide. The insecticidal activity of chlorfenapyr depends on its biotransformation by hepatic cytochrome P450 monooxygenases to tralopyril, which uncouples mitochondrial oxidative phosphorylation and disrupts adenosine triphosphate production. Neither the metabolism of chlorfenapyr nor the mechanism of tralopyril is completely elucidated. Acute human chlorfenapyr poisoning is not well characterized, and best practice in management following acute exposure is unclear. The purpose of this review is to characterize acute human chlorfenapyr poisoning by its clinical course, laboratory investigations, and imaging findings and propose a management plan for acute human chlorfenapyr exposure.
METHODS: We systematically searched PubMed, Web of Science, Google Scholar, and EMBASE from inception to April 2024 across all languages for human chlorfenapyr and tralopyril cases, with descriptions of exposure, clinical manifestations, and clinical course included. Only manuscripts and abstracts from scientific conferences with sufficient clinical data following acute human exposures were included. In vitro studies, animal studies, agricultural studies, environmental impact studies, and non-clinical human studies were excluded. We then reviewed citations of included studies for additional eligible publications. Non-English publications were translated using Google Translate or primarily translated by our authors. The study adhered to Preferred Reporting for Systematic Reviews and Meta-analyses (PRISMA) guidelines for systematic reviews.
RESULTS: We identified 3,376 publications of which 48 met study inclusion criteria, describing 75 unique cases of human poisoning from ingestion, inhalation, dermal exposure, and intra-abdominal injection of chlorfenapyr. No cases of tralopyril exposure were identified. The median time from exposure to symptom onset was six hours (interquartile range 1-48 hours). The most frequent initial or presenting signs/symptoms included diaphoresis, nausea and/or vomiting, and altered mental status. While hyperthermia (≥38 degrees centigrade) was less common at presentation, hyperthermia developed in 61 percent of all patients and was temporally associated with clinical deterioration and death. Most common laboratory abnormalities included elevated blood creatine kinase activity, hepatic aminotransferase activities, and lactate concentration. Imaging studies of the central nervous system often showed extensive symmetrical white matter abnormalities with swelling. Case fatality was 76 percent, and survivors commonly experienced sustained neurological sequelae. Management strategies were highly varied, and the effectiveness of specific medical interventions was unclear.
DISCUSSION: Acute human chlorfenapyr poisoning is characterized by a latent period as long as 14 days, deterioration over hours to days, and can result in serious morbidity and mortality. Development of hyperthermia, likely driven by oxidative phosphorylation uncoupling by tralopyril, is an ominous clinical sign and is temporally associated with clinical decompensation and death. Laboratory abnormalities, particularly elevated creatine kinase activity, hepatic aminotransferase activities, and lactate concentration, were common, but only creatine kinase activity differed amongst survivors and fatalities. Best clinical practice in the management of patients exposed to chlorfenapyr is unclear, and we opine that a conservative approach with close clinical monitoring and supportive care is prudent.
LIMITATIONS: The limitations of all reviews include their inherent retrospective and observational nature as well as publication bias that emphasizes severe outcomes, thus impacting the spectrum of illness and skewing mortality percentage. In addition, we interrogated a finite number of databases for publications on human chlorfenapyr exposure and there were limited cases with laboratory testing to confirm chlorfenapyr poisoning. Analysis of our systematic review was not powered to detect differences between groups, comparative statistics were not performed, and significance is not reported.
CONCLUSIONS: Acute human chlorfenapyr toxicity is characterized by a latent period following exposure, development of new or progression of established signs/symptoms, potential for critical illness, rapid deterioration, serious morbidity, and mortality. A conservative approach to patient management is prudent.
参考来源
- Comstock GT, Nguyen H, Bronstein A, et al. Chlorfenapyr poisoning: a systematic review. Clin Toxicol (Phila). 2024. PMID: 38984827. doi:10.1080/15563650.2024.2367658
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。